Zions Bancorporation National Association UT Has $6.47 Million Stock Position in Eli Lilly and Company $LLY

Zions Bancorporation National Association UT grew its position in Eli Lilly and Company (NYSE:LLY) by 10.2% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 6,018 shares of the company’s stock after buying an additional 557 shares during the period. Zions Bancorporation National Association UT’s holdings in Eli Lilly and Company were worth $6,467,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of Eli Lilly and Company by 1.2% in the 4th quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock valued at $88,087,193,000 after buying an additional 1,006,885 shares during the period. State Street Corp increased its stake in shares of Eli Lilly and Company by 0.6% in the 3rd quarter. State Street Corp now owns 34,726,558 shares of the company’s stock valued at $26,496,364,000 after buying an additional 219,590 shares during the period. Capital Research Global Investors increased its stake in shares of Eli Lilly and Company by 20.9% in the 3rd quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock valued at $19,141,787,000 after buying an additional 4,332,008 shares during the period. Capital World Investors increased its stake in shares of Eli Lilly and Company by 0.4% in the 4th quarter. Capital World Investors now owns 15,031,750 shares of the company’s stock valued at $16,154,619,000 after buying an additional 61,851 shares during the period. Finally, Wellington Management Group LLP increased its stake in shares of Eli Lilly and Company by 4.1% in the 3rd quarter. Wellington Management Group LLP now owns 14,563,780 shares of the company’s stock valued at $11,112,164,000 after buying an additional 574,229 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA approval for a longer-dated EBGLYSS maintenance regimen boosts Lilly’s dermatology franchise and broadens growth beyond obesity and diabetes, while also making the therapy easier for patients to stay on. FDA Ebglyss Decision Adds New Thread To Eli Lilly Growth Story
• Positive Sentiment: Analysts have nudged up FY2026 EPS estimates, reinforcing confidence that Lilly’s earnings momentum remains strong and above consensus expectations. MarketBeat stock background
• Positive Sentiment: Recent reports highlighted strong clinical and commercial momentum across Lilly’s obesity pipeline, including Foundayo and retatrutide, which supports the company’s leadership in GLP-1 and incretin drugs. Focus: Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon
• Positive Sentiment: Jefferies raised its price target and reiterated a Buy rating, adding to the bullish analyst tone around Lilly’s pipeline and valuation. Is Eli Lilly and Company (LLY) One of the 10 Best Dividend Stocks to Buy According to D. E. Shaw?
• Neutral Sentiment: Lilly also announced an Alzheimer’s licensing deal with AlzeCure that expands its neuroscience pipeline, but the financial impact is still early-stage and tied to future milestones. Eli Lilly continues dealmaking roll with $1bn AlzeCure agreement
• Negative Sentiment: Reuters reported some U.S. employers may start dropping coverage for GLP-1 weight-loss drugs in 2027 as usage rises, which could eventually pressure demand for Zepbound and other obesity treatments. Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases

Eli Lilly and Company Stock Down 0.5%

NYSE:LLY opened at $1,138.78 on Thursday. The stock’s fifty day simple moving average is $989.96 and its 200-day simple moving average is $1,015.14. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The firm has a market capitalization of $1.07 trillion, a P/E ratio of 40.45, a P/E/G ratio of 1.25 and a beta of 0.53. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,182.73.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping the consensus estimate of $6.97 by $1.58. The firm had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same period in the previous year, the company posted $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities research analysts expect that Eli Lilly and Company will post 35.8 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th were issued a dividend of $1.73 per share. The ex-dividend date was Friday, May 15th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s payout ratio is currently 24.58%.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on LLY shares. Wolfe Research restated an “outperform” rating and issued a $1,350.00 price target on shares of Eli Lilly and Company in a research report on Thursday, May 21st. HSBC lowered Eli Lilly and Company from a “hold” rating to a “reduce” rating and reduced their price target for the stock from $1,070.00 to $850.00 in a research report on Tuesday, March 17th. Daiwa Securities Group raised their price target on Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. Barclays raised their price target on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a research report on Monday, May 4th. Finally, Bank of America raised their price target on Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the stock a “buy” rating in a research report on Tuesday, May 26th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $1,227.74.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.